CTLT dividend history

Q1'24 net revenue of $982 million decreased 4% as reported, or 6% in constant currency(1), compared to Q1'23. Organic, constant-currency net revenue decreased by 8%, compared to Q1'23. Q1'24 net revenue, excluding COVID revenue of ~$185 million in Q1'23 and ~$100 million in Q1'24, increased 5% compared to Q1'23. Q1'24 net loss of $(715) million, includes non-cash goodwill impairment charges of $700 million. Q1'24 Adjusted EBITDA(1) of $115 million decreased 38% as reported, or 39% in constant currency, compared to Q1'23. Reaffirming FY'24 financial guidance range, which includes net revenue of $4.3 billion to $4.5 billion and Adjusted EBITDA(1) of $680 million to $760 milli

Q4'23 net revenue of $1.07 billion decreased (17)% as reported, or (17)% in constant currency, compared to Q4'22. Organic, constant-currency net revenue decreased (19)%, compared to Q4'22. Fiscal 2023 net revenue of $4.28 billion decreased (11)% as reported, or (9)% in constant currency, compared to fiscal 2022. Organic, constant-currency net revenue decreased (11)% compared to FY'22. Q4'23 net loss of $(86) million and fiscal 2023 net loss of $(232) million. Q4'23 Adjusted EBITDA(1) of $139 million decreased (61)% as reported, or (61)% in constant currency, compared to Q4'22. Fiscal 2023 Adjusted EBITDA(1) of $714 million decreased (43)% as reported, or (42)% in constant c

Q3'23 net revenue of $1.04 billion decreased 19% as reported, or 17% in constant currency(1), compared to Q3'22. Organic, constant-currency net revenue decreased by 19%, compared to Q3'22. Q3'23 net loss of $(227) million, including a goodwill impairment of $210 million. Q3'23 Adjusted EBITDA(1) of $105 million decreased 69% as reported, or 68% in constant currency, compared to Q3'22. Updated FY'23 financial guidance projects net revenue of $4,225 million to $4,325 million and Adjusted EBITDA(1) of $700 million to $750 million. (1) See "Non-GAAP Financial Measures" below and the GAAP to non-GAAP reconciliation provided later in this release. Catalent, Inc. (NYSE:CTLT), the le

Q2'23 net revenue of $1.15 billion decreased 6% as reported, or 2% in constant currency(1), compared to Q2'22. Organic, constant-currency net revenue decreased by 4%, compared to Q2'22. Q2'23 net earnings of $81 million. Q2'23 Adjusted EBITDA(1) of $283 million decreased 9% as reported, or 6% in constant currency, compared to Q2'22. Catalent reiterates full-year guidance, including net revenue of $4,625 million to $4,875 million and Adjusted EBITDA of $1,220 million to $1,300 million. Moderna and Catalent to extend collaboration to broaden manufacturing partnership across multiple products and formats in North America and Europe. Catalent, Inc. (NYSE:CTLT), the global leader in e

Q1'23 net revenue of $1.02 billion, consistent with the prior-year period as reported, but increased 4% in constant currency, compared to Q1'22. Organic, constant-currency net revenue decreased by 1%, compared to Q1'22. Q1'23 net earnings of zero. Q1'23 Adjusted EBITDA(1) of $187 million decreased 26% as reported, or 24% in constant currency, compared to Q1'22. Q1'23 Revenue and Adjusted EBITDA negatively impacted by $54 million due to timing of resolution of previously executed take-or-pay contracts; amount has been paid and is expected to be recognized in Q2'23. Completed acquisition of Metrics Contract Services in October 2022 for $475 million, excluding adjustments. Updated F

Q3'22 net revenue of $1.27 billion increased 21% as reported, or 23% in constant currency, compared to Q3'21. Organic, constant-currency net revenue grew 20%, compared to Q3'21. Q3'22 net earnings of $141 million. Q3'22 Adjusted EBITDA(1) of $339 million increased 24% as reported, or 26% in constant currency, compared to Q3'21. Increasing and tightening FY'22 guidance to reflect projected net revenue growth of 20-23% and Adjusted EBITDA growth of 24-28%, compared to previous projected net revenue growth of 19-22% and Adjusted EBITDA growth of 23-27%. Preliminary FY'23 organic, constant-currency net revenue growth outlook in line with long-term 8-10% growth rate. Catalent, Inc. (N

Q2'22 net revenue of $1.22 billion increased 34% as reported, or 35% in constant currency, compared to Q2'21. Organic, constant-currency net revenue grew 32%, compared to Q2'21. Q2'22 net earnings of $97 million. Q2'22 Adjusted EBITDA(1) of $310 million increased 39% as reported and in constant currency, compared to Q2'21. Increasing and tightening guidance to reflect projected net revenue growth of 19-22% and Adjusted EBITDA growth of 23-27%, compared to previous projected net revenue growth of 16-21% and Adjusted EBITDA growth of 20-27%. Catalent, Inc. (NYSE:CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and s

Q1'22 net revenue of $1.03 billion increased 21% as reported, or 20% in constant currency, compared to Q1'21. Organic, constant-currency net revenue grew 23%, compared to Q1'21. Q1'22 net earnings of $93 million. Q1'22 Adjusted EBITDA(1) of $252 million increased 44% both as reported and in constant currency, compared to Q1'21. Acquired Bettera, a leading manufacturer in the high-growth gummy, soft chew, and lozenge segments of the nutritional supplements market, for $1 billion on October 1, 2021. Increasing guidance range; projecting net revenue growth of 16-21% and Adjusted EBITDA growth of 20-27%. Catalent, Inc. (NYSE:CTLT), the global leader in enabling pharma, biotech, and c

Q4'21 net revenue of $1.19 billion increased 25% as reported, or 22% in constant currency, compared to Q4'20. Organic, constant-currency net revenue grew 26%, compared to Q4'20. Fiscal 2021 net revenue of $4.00 billion increased 29% as reported, or 26% in constant currency, compared to fiscal 2020. Organic, constant-currency net revenue grew 25% compared to FY'20. Q4'21 net earnings of $182 million and fiscal 2021 net earnings of $585 million. Q4'21 Adjusted EBITDA(1) of $348 million increased 30% as reported, or 27% in constant currency, compared to Q4'20. Announces proposed $1 billion acquisition of Bettera, a leading manufacturer in the high-growth gummy, soft chew, and lozenge

Q3'21 net revenue of $1.05 billion increased 38% as reported, or 35% in constant currency, compared to Q3'20. Organic, constant-currency net revenue grew 35%, compared to Q3'20. Q3'21 net earnings of $232 million; includes a $184 million gain from the sale of the blow-fill-seal business. Q3'21 Adjusted EBITDA(1) of $274 million increased 48% as-reported, or 44% in constant currency, compared to Q3'20. Q3'21 Biologics segment net revenue of $544 million more than doubled compared to Q3'20. Increasing guidance to reflect projected net revenue growth of 25-28% and Adjusted EBITDA growth of 30-35% compared to projected net revenue growth in previous guidance of 23-28% and Adjusted EB

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced financial results for the second quarter of fiscal 2021, which ended December 31, 2020. “Our second quarter results reflect robust organic growth in our Biologics segment, and our increased guidance reflects our expectation of continued strong results for these offerings for the remainder of our fiscal year. Additional capacity in our drug product and drug substance offerings will come on line in the second half of our fiscal y